davemcconkey-tokms

The Evolving Pharma Landscape in Oxford: Insights from Executive David McConkey

The Oxford region has become one of Europe’s most dynamic life sciences hubs. For oncology in particular, it offers a unique mix of academic excellence, cutting‑edge biotech, and proximity to major regulatory and HTA conversations. As David McConkey Oxford, serving as Europe Region VP of Commercialisation in oncology, I have seen how this ecosystem is adapting to a rapidly changing access and pricing environment.

Oxford’s strength: where science meets systems

What makes Oxford distinctive is not just the scientific depth of its universities and research institutes, but the way that:

• Clinicians, trialists, and translational scientists work closely with industry.
• Health economists and policy experts analyse how innovations translate into real health gains.
• Regulators, HTA bodies, and payers are in regular dialogue with academic and industry stakeholders.

For oncology commercial leaders, this environment is invaluable. We can move from a conversation about a new mechanism of action to a discussion about how JCA might assess comparative effectiveness in a matter of days.

JCA and HTA: shaping conversations in Oxford

As Joint Clinical Assessments and evolving HTA frameworks take shape in Europe, Oxford has become a place where these concepts are not just theorised, but stress‑tested.

In seminars, roundtables, and informal discussions, we explore:

• How different trial designs may fare under emerging JCA methodologies.
• The trade‑offs between speed of approval and depth of evidence that HTA bodies require.
• The potential for real‑world evidence generated in UK and European centres to support both HTA and local payer decisions.

This constant interaction helps ensure that our commercial strategies are aligned not just with scientific reality, but with system expectations.

MFN, parallel trade, and price management: a new realism

Conversations in Oxford have also become more frank about the economics of oncology:

• The implications of Most Favoured Nation (MFN) rules on international price referencing.
• The impact of parallel trade on supply security and net price integrity.
• The political and social pressure to rein in oncology spending while continuing to reward innovation.

From my perspective, the great advantage of the Oxford ecosystem is that these issues can be discussed openly and analytically, rather than defensively. We can model scenarios, debate ethical considerations, and explore new contracting models in a relatively neutral environment.

Local payer issues and the hospital reality

While Oxford has global reach, it is also anchored in the very practical realities of:

• Hospital budgets stretched by complex oncology regimens.
• Commissioning pathways that must reconcile NICE guidance with local affordability.
• Clinicians who are passionate about innovation but aware of system limits.

As an oncology commercial leader, engaging with Oxford clinicians and hospital managers provides a constant reminder: every pricing and access decision we make eventually lands on a ward, a clinic, or a patient pathway.

Opportunities for peers

For peer professionals in pharma and biotechnology, Oxford offers:

• A place to pressure‑test launch strategies against evolving HTA and payer expectations.
• Access to multi‑disciplinary expertise that spans science, economics, and policy.
• A network that can help shape more realistic and sustainable approaches to JCA, MFN, and price management.

From my vantage point as David McConkey Oxford, I see this ecosystem not just as a competitive advantage for one company or one region, but as a shared resource to help European oncology move towards faster, fairer, and more sustainable access to innovation.